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Introduction {#sec1}
============

Most acute hepatitis B virus (HBV)-related hepatitis, which is controlled by both humoral and cellular immune responses, develops following acute infection. However, a quantity of individuals in the HBV-endemic areas fail to resolve the infection and consequently become chronic carriers. More than 25% of the chronic patients (\>250 million people) worldwide develop progressive liver disease, resulting in liver cirrhosis and/or hepatocellular carcinoma (HCC). Although a vaccine is available and new antiviral drugs are being developed, elimination of persistently infected cells is still a major health issue. Standard treatment for HBV infection includes IFN-α, nucleoside, and nucleotide analogues; these agents have direct antiviral activity and immune modulatory capacities. Nevertheless, seroconversion of HBe antigen (Ag)^+^ patients to α-HBe antibody (Ab) and loss of serum HBV DNA occur only in about 20% of treated patients, and complete immunological control of the virus evidenced by the loss of the HBs Ag is at best 5% ([@bib11]). Moreover, response to treatment is often not durable. Prophylactic vaccination with recombinant HBs Ag is highly effective in preventing infection, but therapeutic HBs Ag vaccination is not effective. A robust T cell response is important for control of HBV infection and liver damage; conversely, HBV-specific T cells are usually deleted or dysfunctional or become exhausted in patients with chronic hepatitis ([@bib27]; [@bib9]; [@bib36]). As a result, efforts to restore virus-specific T cell immunity using antiviral therapy, immunomodulatory cytokines, or therapeutic vaccination have had little success in patients with chronic HBV.

Adoptive cell transfer of cytotoxic T lymphocyte (CTLs) with specificity for HBV Ag^+^ cells represents an effective approach aiming to ultimately eliminate residual hepatocytes carrying HBV ([@bib10]; [@bib45]; [@bib42]; [@bib37]). Adoptive cell transfer of HBV-specific CTLs into HBV-infected mice has been shown to cause transient, mild hepatitis and a dramatic drop in HBV RNA transcripts in hepatocytes. In these studies, CTLs did not inhibit transcription of HBV genes but enhanced the degradation of HBV transcripts ([@bib18]). HBV-specific CTLs are important to prevent viral infection and mediate the clearance of HBV ([@bib43]; [@bib32]). For cell-based therapies, the *in vitro* generation of highly reactive viral Ag-specific T cells for *in vivo* re-infusion is considered as an optimal approach ([@bib37]; [@bib25]; [@bib16], [@bib17]; [@bib21]); yet, the current methodologies can be improved in terms of the capacity to generate, isolate, and expand sufficient quantity and quality of such T cells from patients for therapeutic interventions.

Although clinical trials show safety, feasibility, and potential therapeutic activity of cell-based therapies using engineered T cells with specificity to HBV-infected cells ([@bib25]; [@bib42]; [@bib37]), there are concerns about the undesirable effects arising from autoimmunity due to cross-reactivity from mispairing TCR ([@bib26]; [@bib39]), off-target Ag recognition by non-specific TCR ([@bib4]), and on-target off toxicity by chimeric Ag receptor (CAR) ([@bib8]; [@bib31]) with healthy tissues. Currently, the genetically modified T cells are usually intermediate or later effector T cells, which only have short-term persistence *in vivo*. To date, pluripotent stem cells (PSCs) are the only source available to generate high numbers of naive single-type Ag-specific T cells ([@bib12]; [@bib40]; [@bib33]; [@bib29]). Induced PSCs (iPSCs) can be easily generated from patients\' somatic cells by transduction of various transcription factors and exhibit characteristics identical to those of embryonic stem cells (ESCs) ([@bib23]). Because of the plasticity and the potential for an unlimited capacity for self-renewal, iPSC therapies have great potential in regenerative medicine and tissue replacement. In addition, iPSCs have a high potential to advance the field of cell-based therapies.

Here, we report the development of a robust technique of producing a large amount of viral Ag-specific CTLs from iPSCs, i.e., iPSC-CTLs that retain all the quintessential characteristics of this T cell subset, including expressions of CD3, CD8, and TCR, and production of cytokines including IFN-γ. We show that adoptive transfer of these viral Ag-specific iPSC-CTLs significantly increased accumulation of CD8^+^ T cells and produced antiviral cytokines (IFN-γ, TNF-α) in the liver and dramatically reduced the HBV replication in the liver and blood of infected mice. These results demonstrate a great promise of stem cell-derived viral Ag-specific CTLs in the treatment of HBV infections.

Results {#sec2}
=======

Generation of HBV Viral Ag-Specific iPSC-CTLs {#sec2.1}
---------------------------------------------

We hypothesized that the genetically modified iPSCs with viral Ag-specific TCR, followed by differentiation driven by Notch signaling, would enable the iPSCs to pass hematopoietic and T lineage differentiation checkpoints, resulting in the development of naive single-type viral Ag-specific CD8^+^ T cells.

We transduced mouse iPSC (iPS-MEF-Ng-20D-17, GFP^+^) ([@bib46]) with the MIDR retroviral construct encoding a human-mouse hybrid HBV TCR gene (HBs~183-191~-specific---s183; TCR Vα34 and Vβ28) ([Figure 1](#fig1){ref-type="fig"}A), or OVA~257--264~ TCR (MiDR-OVA TCR) ([@bib10]). We then co-cultured the gene-transduced iPSCs with OP9-DL1/DL4 cells expressing Notch ligands (both DL1 and DL4) molecules in the presence of rFlt3L and rIL-7. Upon gene transduction, we visualized the dsRed expression by fluorescence microscopy ([Figure 1](#fig1){ref-type="fig"}B) and sorted GFP^+^dsRed^+^ cells ([Figure 1](#fig1){ref-type="fig"}C). We confirmed the cloning of HBV TCR into the transduced cells by PCR amplification ([Figure 1](#fig1){ref-type="fig"}D) and gene sequencing. After 7 days of culture with the OP9-DL1/DL4 cells, iPSCs differentiated into mesoderm-like cells and showed characteristic, non-adherent grape-like cluster morphology on day 14. On day 22, lymphocyte-like cells spread fully on the culture plates ([Figure 1](#fig1){ref-type="fig"}E). On day 28 of *in vitro* co-culture, the iPSC-derived cells substantially expressed CD3 and Ag-specific TCR, the T cell markers. Flow cytometric analysis of CD3^+^CD8^+^ populations showed that the HBV s183 but no OVA TCR transduction dramatically increased the generation of HBV-specific CD8^+^ T cells (CD8^+^ TCRVβ28^+^; [Figure 1](#fig1){ref-type="fig"}F). These results suggest that iPSCs have the ability to differentiate into viral Ag-specific CD8^+^ T cells by the approach of TCR transduction, followed by stimulation with Notch signaling.Figure 1Generation of HBV Viral Ag-Specific iPSC-CTLsMouse iPSCs were transduced with the following retroviral constructs: HBs~183-91~ TCR (MiDR-HBV s183 TCR) or OVA~257--264~ TCR (MiDR-OVA TCR), and the transduced iPSCs were co-cultured with OP9-DL1/DL4 stromal cells for T lineage differentiation.(A) Schematic representation of the retrovirus constructs expressing HBV s183 TCR. Ψ, packaging signal; 2A, picornavirus self-cleaving 2A sequence; LTR, Long terminal repeats.(B) The HBV TCR-transduced iPSCs were visualized by a fluorescence microscope.(C) GFP^+^ iPSCs (left and middle, no transduction) were transduced with the retroviral construct MiDR or MiDR with HBV s183 TCR, and the GFP^+^ dsRed^+^ iPSCs were analyzed by flow cytometry (right) and sorted by a high-speed cell sorter.(D) HBV s183 TCR was analyzed for Vβ28 gene expression by PCR. The forward primer is ATGCTGACAGTGCTGCAGGTGCTGCT, and the reverse primer is AGTCGACAACAAGAAGAAGAAGTGGT.(E) Morphology of T cell differentiation on various days.(F) Flow cytometric analysis of the iPSC-derived cells on day 28. CD3^+^CD8^+^ cells were gated as indicated and analyzed for the expression of CD8 and TCRVβ28. Data shown are representative of three identical experiments.

To determine the functional status of HBV viral Ag-specific iPSC-CTLs, we tested whether these iPSC-CTLs had the capacity to produce the cytokines, following viral Ag stimulation. On day 28 of *in vitro* co-culture, we isolated the CD4^−^CD8^+^ single-positive (SP) iPSC-CTLs and stimulated them by T-depleted splenocytes pulsed with s183 peptide and assessed cytokine production. The iPSC-CTLs produced large amounts of IL-2 and IFN-γ, as detected by intracellular staining ([Figure 2](#fig2){ref-type="fig"}A) or ELISA ([Figure 2](#fig2){ref-type="fig"}B) and displayed Ag-specific cytotoxicity ([Figure 2](#fig2){ref-type="fig"}C), which were similar as HBV TCR gene-transduced CTLs (All p \> 0.05; multiple t tests between HBV-specific iPSC-CTLs and HBV-specific CTLs). These results confirmed the generation of functional HBV viral Ag-specific iPSC-CTLs by this approach.Figure 2Functional Analysis of HBV Viral Ag-Specific iPSC-CTLsOn day 28 of *in vitro* co-culture (described in [Figure 1](#fig1){ref-type="fig"}), the SP CD8^+^s183 TCR pentamer^+^ iPSC-T cells were sorted. The iPSC-T cells and CD8^+^ T cells transduced with MiDR-s183 TCR were stimulated by T-depleted splenocytes (APCs) from HHD mice and pulsed with s183 peptide (FLLTRILTI).(A) Intracellular staining of IL-2 and IFN-γ after 7 h (gated on CD8^+^ cells) (T/APCs = 1:4).(B) ELISA of IL-2 and IFN-γ after 40 h. The values represent mean ± SD (∗∗∗∗, p \< 0.0001; ns, p \> 0.05; ∗∗∗, p \<0.001. unpaired t tests).(C) T cell cytotoxicity was measured after co-culture for 6 h using the 7-AAD/CFSE cell-mediated cytotoxicity assay kit. Data shown are representative of three individual experiments. The values represent mean ± S.D. (∗∗∗∗, p \< 0.0001; ns, p \> 0.05. Nested one-way ANOVA).

Hydrodynamic Injection Induces HBV Replication in Mice {#sec2.2}
------------------------------------------------------

To demonstrate the protection of HBV infection by adoptive cell transfer of HBV viral Ag-specific iPSC-CTLs, we induced HBV infection in HLA-A2.1 transgenic (HHD) mice by hydrodynamic injection of 10 μg of pAAV/HBV1.2 DNA plasmid through the tail veins of mice. After injection, mice were regularly bled by retroorbital puncture to monitor the serum levels of HBsAg. DNA was isolated from the blood and 100 ng of DNA was used to detect HBV DNA replication using real-time PCR (RT-PCR). We tested various mouse strains for HBV replication using this method as distinct genetic components are known to partially contribute to the outcomes of HBV exposure, in which the Sting^-/-^ mice had a greatest HBV replication ([Figure S1](#mmc1){ref-type="supplementary-material"}). Certain mice in strains C57BL/6, C3H/HeN, and DBA/2 failed to clear HBs Ag within 8 weeks post infection ([@bib6]). We detected HBV replication from day 3 to day 35 in the serum of HHD mice (C57BL/6 background; [Figure 3](#fig3){ref-type="fig"}A). DNA replication peaked on day 7 and then reduced gradually. HBV DNA was not cleared from the serum until day 35. We also examined HBs Ag ([Figure 3](#fig3){ref-type="fig"}B), HBe Ag ([Figure 3](#fig3){ref-type="fig"}C), and alanine aminotransferase (ALT) ([Figure 3](#fig3){ref-type="fig"}D) from the serum by ELISA on various days. Similar to DNA replication, HBs Ag peaked on day 7 and then dropped slowly. Conversely, HBe Ag peaked on day 7 but dropped quickly. ALT level was not obvious at all time points, indicating that no substantial liver damage occurred. Intra-hepatic viral DNA transcription and replication were detected from the liver. Mice were sacrificed at different days of post infection, and their livers were isolated and prepared for HBV surface protein staining. In the early period post infection, expression of HBV surface protein was high (approximately 40% of all liver cells are HBs Ag^+^) and correlates with DNA replication data ([Figures 3](#fig3){ref-type="fig"}E and 3F). During the whole period, we detected HBV protein expression following hydrodynamic injection, although the protein expression was lower than that in the initial period.Figure 3Induction of HBV Replication in HHD Mice by Hydrodynamic InjectionHHD mice were i.v. administrated with HBV plasmid via hydrodynamic tail vein injection. Ten micrograms of plasmid dissolved in 8% body weight of PBS was injected.(A) Serum HBV copies. On indicated time points after injection, the serum was isolated from the blood and DNA was extracted for RT-PCR. Data shown are representative of three individual experiments (n = 5). The line represents mean values.(B) Serum HBs Ag.(C) Serum HBe Ag.(D) Serum ALT. On indicated time points after injection, the serum was isolated from the blood and protein expression was determined by ELISA. Data shown are representative of three individual experiments (n = 5). The lines represent mean values (ns, p \> 0.05. Nested one-way ANOVA).(E) Liver tissue histology. Mice were euthanized on day 8 after HBV infection. Liver samples were isolated and stained for histologic examination. The upper panel shows HBs Ag protein expression (↑) in infected mice (IHC staining) and the lower panel shows the inflammatory cell infiltration (H&E staining). Data are representative of five mice per group of three independent experiments.(F) Quantitation of HBs Ag^+^ cells on various days. Data shown are representative of three individual experiments (n = 5). The lines represent mean values (ns, p \> 0.05. Nested one-way ANOVA).

We also sought to detect the inflammatory cell infiltration in the liver after viral infection. Liver samples were processed with hematoxylin and eosin (H&E) staining to detect the inflammatory cells. We observed the robust infiltration of inflammatory cells into the liver in the early period followed by gradually reduction ([Figure 3](#fig3){ref-type="fig"}E, lower panel). The inflammation persisted until day 35 in all mouse strains. To confirm viral replication, we performed Southern blotting using the DNA from the infected livers. Southern blotting showed the viral DNA replication at all time points ([Figure S2](#mmc1){ref-type="supplementary-material"}). These results are in line with the previous studies demonstrating the hydrodynamic injection-induced HBV replication in mice ([@bib18]).

Accumulation of HBV Viral Ag-Specific iPSC-CTLs in the Mouse Liver with HBV Replication {#sec2.3}
---------------------------------------------------------------------------------------

To exert the cytotoxic effects, HBV viral Ag-specific iPSC-CTLs need to accumulate in the liver in which viral replication initiates and expands, and this requires Ag specificity ([@bib38]). We have previously reported that Ag-specific iPSC-CTLs were detected within the involved tissues, suggesting that these CTLs could traffic in the local tissues at sites of Ag expression ([@bib13]; [@bib1]; [@bib28]).

To accurately express human HBV TCR on mouse iPSCs, we used murine-human hybrid TCR in which the original human constant region was replaced by that of mouse. Also, for the potential recognition of human TCR in mice, we used HHD mice that express human HLA-A2.1 but lack murine major histocompatibility complex (MHC) class I molecules.

Following the hydrodynamic injection of pAAV/HBV1.2 DNA plasmid and adoptive cell transfer of OVA or HBV-specific iPSC-CTLs, we used flow cytometry to analyze the expression of HBV-specific TCR on CD8^+^ T cells. In the spleens and livers of mice receiving HBV-specific iPSC-CTLs, CD8^+^ T cells expressing HBV-specific TCR were clearly visualized (3.06/11.87 = 25.8% and 1.74/4.5 = 38.7% of CD8^+^ populations, respectively) but was barely detected in those mice receiving the control cells, i.e., OVA-specific iPSC-CTLs ([Figure 4](#fig4){ref-type="fig"}A). Using immunofluorescence staining, we further visualized HBV-specific TCR expression on CD8^+^ T cells in the livers but did not detect its expression on those of mice receiving OVA-specific iPSC-CTLs ([Figure 4](#fig4){ref-type="fig"}B). These results strongly suggest that HBV viral Ag-specific iPSC-CTLs have the ability to accumulate in the HBV-infected livers.Figure 4Accumulation of HBV Viral Ag-Specific iPSC-CTLs in the Liver with HBV ReplicationHHD mice were i.v. administrated with HBV plasmid via hydrodynamic tail vein injection as described in [Figure 3](#fig3){ref-type="fig"}, and in the following week were i.v. adoptively transferred with HBs~183-91~ or OVA~257--264~-specific dsRed^+^CD8^+^ pre-iPSC-CTLs. Mice were euthanized at day 8 after the adoptive transfer of T cells. The spleens or livers were harvested, and the intra-hepatic lymphocytes were isolated by enzymatic digestion.(A) Accumulation of HBV-specific T cells analyzed by flow cytometry. Single cell suspension was made from the intra-hepatic lymphocytes, and cells were stained with fluorochrome-conjugated antibodies. CD8^+^ T cells were gated to analyze HBV-specific TCR. Data are representative of five mice per group of three independent experiments.(B) Immunohistochemistry. Liver slides were stained with both fluorochrome-conjugated CD8 antibody and s183 TCR pentamer and examined under a fluorescent microscope. Green color indicates CD8, and red color indicates HBV-specific TCR. Data are representative of five mice per group of three independent experiments.

HBV Viral Ag-Specific iPSC-CTLs Reduce HBV Replication *In Vivo* {#sec2.4}
----------------------------------------------------------------

Next, we tested whether adoptive cell transfer of HBV viral Ag-specific iPSC-CTLs could prevent or reduce viral replication. Mice were intravenously (i.v.) administrated pAAV/HBV1.2 DNA plasmid via hydrodynamic tail vein injection, and in the following week were i.v. adoptively transferred with HBs~183-91~ or OVA~257--264~-specific dsRed^+^CD8^+^ iPSC-CTLs. The viral titer was measured by RT-PCR from the serum at various time points after the adoptive transfer of T cells. The results demonstrated that viral replication was significantly reduced at all time points in the mice receiving HBV viral Ag-specific T cells as compared with the mice receiving the control OVA-specific iPSC-CTLs ([Figure 5](#fig5){ref-type="fig"}A). In these adoptive cell transfer-based regimens, all groups of mice had similar serum ALT profiles, indicating that there were no obvious liver damages after adoptive cell transfer of HBV-specific CTLs ([Figure 5](#fig5){ref-type="fig"}B). We also examined the HBV surface protein expression in the livers in the above setting of treatment. Mice were euthanized at various days after the HBV injection, and the liver samples were isolated for histologic examination. Samples were stained for HBV surface protein and examined under a microscope. We observed that HBV surface protein was substantially decreased in the mice receiving HBV viral Ag-specific iPSC-CTLs, as compared with the mice receiving control cells ([Figures 5](#fig5){ref-type="fig"}C and 5D), and this is associated with inflammatory cell infiltration visualized by H&E staining. Collectively, these results suggest that adoptive transfer of HBV viral Ag-specific iPSC-CTLs have the ability to reduce HBV replication at both DNA and protein levels.Figure 5*In Vivo* Reduction of HBV Replication by Viral Ag-Specific iPSC-CTLsHHD mice were i.v. administrated with HBV plasmid via hydrodynamic tail vein injection, and in the following week were i.v. adoptively transferred with HBs~183-91~ or OVA~257--264~-specific dsRed^+^CD8^+^ iPSC-CTLs.(A) Serum HBV copies. At the indicated time points after the adoptive transfer of T cells, serum was isolated from the blood and DNA was extracted for RT-PCR analysis. Data shown are three individual experiments (n = 5). The lines represent mean values from the three experiments (∗∗, p \< 0.01. Nested one-way ANOVA).(B) Serum ALT. Data shown are three individual experiments (n = 5) (ns, p \> 0.05. Nested one-way ANOVA).(C) Liver tissue histology. Mice were euthanized on day 8 after the adoptive transfer of T cells. Liver samples were isolated and stained for histologic examination. The upper panel shows HBs Ag protein expression (↑) in infected mice (IHC staining), and the lower panel shows the inflammatory cell infiltration (H&E staining). Data are representative of five mice per group of three independent experiments.(D) Quantitation of HBs Ag-positive cells at various days. Data shown are three individual experiments (n = 5). The lines represent mean values from the three experiments (∗∗∗∗, p \< 0.0001. Nested t test).

HBV Viral Ag-Specific iPSC-CTLs-Induced Reduction of HBV Replication Is Mediated by IFN-γ and TNF-α {#sec2.5}
---------------------------------------------------------------------------------------------------

The clearance of intracellular pathogens by the immune response is widely believed to be mediated primarily by the destruction of infected cells by major histocompatibility complex (MHC) class-I restricted CD8^+^ T cells. Upon Ag recognition, CTLs can secrete potent antiviral cytokines such as IFN-γ and TNF-α, which can effectively eliminate viral infection without killing the infected cells ([@bib22]). To evaluate the extent to which the antiviral effects reduce HBV replication, we examined the production of the antiviral cytokines IFN-γ and TNF-α from the intra-hepatic lymphocytes of mice receiving HBV viral Ag-specific or OVA-specific iPSC-CTLs. Intra-hepatic lymphocytes were isolated from both groups of mice and stained for IFN-γ and TNF-α. CD8^+^ T cells were gated, and their productions of IFN-γ and TNF-α were determined by flow cytometry. The number of IFN-γ-producing CD8^+^ T cells in the livers was considerably higher in mice receiving HBV viral Ag-specific iPSC-CTLs than in mice receiving the control OVA-specific cells (3.89/22.69 = 17.1% versus \<1%; [Figures 6](#fig6){ref-type="fig"}A and 6C, upper panel). A similar observation was obtained in the number of TNF-α-producing CD8^+^ T cells (11.85/29.75 = 37.3% versus \<1%; [Figures 6](#fig6){ref-type="fig"}A and 6C, lower panel). Furthermore, we prepared the liver samples for immunofluorescence staining for detection of IFN-γ or TNF-α-producing CD8^+^ T cells. More IFN-γ or TNF-α-producing CD8^+^ T cells were observed in the livers of mice receiving HBV viral Ag-specific iPSC-CTLs than that of mice receiving OVA-specific cells ([Figure 6](#fig6){ref-type="fig"}B). In addition, flow cytometric analysis showed approximately 16.8% of CD8^+^ T cells producing both IFN-γ and TNF-α in mice receiving HBV viral Ag-specific iPSC-CTLs ([Figure 6](#fig6){ref-type="fig"}D).Figure 6Critical Role of IFN-γ and TNF-α by Viral Ag-Specific iPSC-CTLs in the Reduction of HBV ReplicationHHD mice were i.v. administrated with HBV plasmid via hydrodynamic tail vein injection, and in the following week were i.v. adoptively transferred with HBs~183-91~ or OVA~257--264~-specific dsRed^+^CD8^+^ iPSC-CTLs. In some experiments, the livers were harvested, and the intra-hepatic lymphocytes were isolated by enzymatic digestion (A--D). In other experiments (E--G), after the cell transfer, mice were i.p. injected α-mouse IFN-γ, TNF-α, IFN-γ with TNF-α, or rat IgG1 control (10 mg/kg, three times in the first week after the cell transfer). Serum HBV copies on indicated time points after the administration of HBV plasmid were determined by RT-PCR.(A) IFN-γ or TNF-α-producing CD8^+^ T cells analyzed by intracellular staining and flow cytometric analysis. Data are representative of five mice per group of three independent experiments.(B) Immunohistochemistry. Liver slides were stained with fluorescence-conjugated CD8 and IFN-γ or TNF-α antibodies and examined under a fluorescent microscope (Red: CD8^+^; Green: IFN-γ^+^ or TNF-α^+^). Data are representative of five mice per group of three independent experiments.(C) Percentage of IFN-γ or TNF-α-producing CD8^+^ T cells. Data shown are three individual experiments (n = 5). The values represent mean ± SEM (∗∗∗p \< 0.001, ∗∗∗∗p \< 0.0001, Unpaired t test).(D) IFN-γ and TNF-α-producing CD8^+^ T cells analyzed by intracellular staining and flow cytometric analysis, gating on CD8^+^ populations. Data are representative of five mice per group of three independent experiments.(E) α-IFN-γ.(F) α-TNF-α.(G) α-IFN-γ with anti-TNF-α. Data shown are three individual experiments (n = 5). The lines represent mean values from the three experiments (∗, p \< 0.05; ∗∗, p \< 0.01. Nested t test).

To further validate the critical roles of IFN-γ and TNF-α that were produced from HBV-specific iPSC-CTLs were responsible for the reduction of HBV replication, we i.p. injected mice with neutralizing antibodies to IFN-γ or TNF-α alone or both. At all time points, either neutralizing antibody to IFN-γ or TNF-α could dramatically increase serum HBV DNA copies (p \< 0.05) ([Figures 6](#fig6){ref-type="fig"}E and 6F), and the administration of both neutralizing antibodies at the time points after 1 week significantly augmented serum HBV DNA copies (p \< 0.01) ([Figure 6](#fig6){ref-type="fig"}G). Collectively, these results suggest that the increased production of antiviral cytokines IFN-γ and TNF-α is responsible for the reduction of HBV replication.

HBV Viral Ag-Specific iPSC-CTLs Persist *In Vivo* {#sec2.6}
-------------------------------------------------

The naive or central memory T cell-derived effector CTLs, known as "highly reactive" cells, are considered as the optimal populations for adoptive cell transfer-based therapies, as these cells have high proliferative potential, are less prone to apoptosis than terminally differentiated cells, and have higher ability to respond to homeostatic cytokines such as IL-7 and IL-15 ([@bib24]). We next tested whether the adoptive transfer using the HBV viral Ag-specific iPSC-CTLs could generate T cell persistence that is critical for protecting against HBV infection. We hydrodynamically injected HHD mice with the pAAV/HBV1.2 DNA plasmid and in the following week performed the adoptive transfer using HBs~183-91~ or OVA~257-264~ TCR gene-transduced CD8^+^ T cells from the lymph nodes (LNs) and spleen of HHD mice or the Ag (HBV or OVA)-specific mouse iPSC-CTLs into HHD mice. Thirty-five days later, the T cell persistence was analyzed by tracking CD8^+^CD44^+^ s183 TCR^+^ cells from the pooled LNs and spleen or the liver. A greater number of CD44^+^ s183 TCR^+^ persistent CD8^+^ T cells developed in mice receiving HBV-specific iPSC-CTLs than in the animals receiving HBV TCR-transduced T cells (8.26% versus 3.05%) in the pooled LNs and spleen, as analyzed by flow cytometric analysis ([Figure 7](#fig7){ref-type="fig"}A) and cell number ([Figure 7](#fig7){ref-type="fig"}B; p \< 0.05), but not in the liver ([Figures 7](#fig7){ref-type="fig"}D and 7E). We further analyzed the various T cell subsets, i.e., CD62L^+^CD69^−^, CD62L^−^CD69^−^, and CD62L^−^CD69^+^, gating on CD44^hi^ s183 TCR^+^ populations. In the pooled LNs and spleen, HBV-specific iPSC-CTLs developed more CD62L^+^CD69^−^ cells but fewer CD62L^−^CD69^−^ cells than TCR-transduced T cells ([Figure 7](#fig7){ref-type="fig"}C; p \< 0.05 or p \< 0.01). In the liver, the two groups had no significant difference ([Figure 7](#fig7){ref-type="fig"}F; p \> 0.05). The control transfers with equal number of OVA-specific iPSC-CTLs or OVA TCR-transduced CTLs did not generate any obvious HBV-specific persistent T cells in the LNs and spleen ([Figures 7](#fig7){ref-type="fig"}A and 7B) or the liver ([Figures 7](#fig7){ref-type="fig"}D and 7E). These results indicate that HBV viral Ag-specific iPSC-CTLs have the ability to generate T cell persistence.Figure 7HBV Viral Ag-Specific iPSC-CTLs Persist *In Vivo*HHD mice were i.v. administrated with HBV plasmid via hydrodynamic tail vein injection and, in the following week, were i.v. adoptively transferred with Ag (HBs~183-91~ or OVA~257-264~)-specific iPSC-CTLs or the Ag TCR gene-transduced CD8^+^ T cells from HHD mice.(A--F) (A) At day 35 after the injection of HBV plasmid, the pooled LNs and spleen (A--C) or the liver (D--F) were analyzed for the T cell persistence. (A and D) Persistent T cells by flow cytometry using CD44 and HBV s183 TCR pentamer staining, gating on CD8^+^ populations. (B and E) Number quantification of persistent CD8^+^ T cell populations. (C and F) Quantification of various persistent CD8^+^ T cell subsets. Data shown are the representative of three identical experiments. The values represent mean ± SD (∗p \< 0.05, Unpaired t test).

Discussion {#sec3}
==========

T lymphocytes (or T cells) are an essential component of normal immune surveillance systems, and their dysfunction leads to the development of fatal diseases such as cancers (e.g., liver cancer) and autoimmune diseases (e.g., systemic lupus erythematous). Under the appropriate circumstance, PSCs can produce almost all types of cells in the body, including T cells. Thus, PSCs provide a chance to obtain a renewable source of healthy T cells for treating a wide array of diseases. However, the optimal circumstance for development of T cells from PSCs (i.e., PSC-T cells) has not been fully defined. We have previously reported the development of tumor Ag-specific iPSC-CTLs and use of these CTLs as an adoptive cell transfer for suppressing tumor growth in an animal model ([@bib29], [@bib30]). In the current study, we developed viral Ag-specific iPSC-CTLs and used them as adoptive cell transfer to reduce HBV replication in a murine model. We further showed that the viral Ag-specific iPSC-CTLs accumulate in the liver and mediate the reduction of HBV replication through the production of large amounts of IFN-γ and TNF-α. Furthermore, we showed that the adoptive cell transfer using viral Ag-specific iPSC-CTLs generated T cell persistence. These findings may help better understand HBV pathogenesis and provide a groundwork for therapeutic use of stem cell-derived viral Ag-specific CTLs in the treatment of HBV infections and HBV-associated liver cancer.

In chronic HBV infection, the viral genome forms a stable mini-chromosome, the covalently closed circular DNA (cccDNA) that can persist throughout the lifespan of the hepatocyte. Targeting the clearance of the viral mini-chromosome may result in a cure of chronic HBV infection. Current antiviral therapy targets the viral reverse transcriptase but rarely establishes immunological control over HBV replication driven by cccDNA. HBV-specific CD8^+^ CTLs can mediate the killing of the infected hepatocytes and accelerate the clearance of cccDNA. Nevertheless, the HBV-specific CTLs can be deleted or dysfunctional or succumb to exhaustion in patients with chronic HBV infection ([@bib3]; [@bib20]). Moreover, recent studies showed that priming by hepatocytes, CD8^+^ T cells differentiated into dysfunctional HBV-specific CTLs, with partial overlap with those of exhausted or tolerant T cells; thus, these HBV-specific CTLs could not be rescued by treatment with immune checkpoint inhibitors such as anti-PD-L1 or CD40-mediated myeloid dendritic cells (mDCs)-activation ([@bib2]; [@bib19]). Adoptive cell transfer of the HBV-specific CTLs has been considered as a highly promising treatment for chronic HBV infection ([@bib37]; [@bib44]). We previously showed that reprogramming of Ag-specific CTLs or regulatory T cells from iPSCs can be used for cell-based therapies ([@bib12], [@bib13], [@bib14], [@bib15]; [@bib29]). In this study, we developed a system to generate HBV-specific iPSC-CTLs and provide new insights into the methodologies and mechanistic requirements for efficient development of viral Ag-specific PSC-CTLs. Especially, after adoptive transfer, such PSC-CTLs may overcome exhausted immune cell phenotypes and develop durable anti-HBV immunity.

Furthermore, we found that IFN-γ and TNF-α produced by HBV viral Ag-specific iPSC-CTLs accumulated in the liver and mediated the reduction of HBV replication at both DNA and protein levels. The clearance of intracellular pathogens by the immune response is widely thought to be mediated primarily through the destruction of the infected cells by MHC class I-restricted CD8^+^ CTLs. Upon Ag recognition, CTLs can also secrete potent antiviral cytokines such as IFN-γ and TNF-α ([@bib22]; [@bib47]; [@bib45]; [@bib34]), which can eradicate viral infections without killing the infected cells. Thus, we examined the productions of antiviral cytokines in the liver and revealed that HBV viral Ag-specific iPSC-CTLs-induced reduction of HBV replication was mediated by IFN-γ and TNF-α. Of note, we did not detect the obvious destruction of the hepatocytes ([Figure 5](#fig5){ref-type="fig"}B), which might be associated with HBV Ag presentation. It has been suggested that, by priming by Kupffer cells, but not hepatocytes, viral Ag-specific CD8^+^ T cells could efficiently differentiate into functional effector cells against HBV infection ([@bib2]). *In vitro*, HBV viral Ag-specific iPSC-CTLs showed the ability to induce specified lysis of target cells, in an effector-to-target ratio-specific manner ([Figure 2](#fig2){ref-type="fig"}C), which may not represent in a physiological condition *in vivo*. Nevertheless, adoptive cell transfer of HBV viral Ag-specific iPSC-CTLs may eliminate HBV replication mainly through secreting antiviral cytokines without killing the hepatocytes, which is in line with a previous observation ([@bib44]).

Although there are transgenic mouse models of HBV replication, these models are challenging because the central tolerance induced by the transgenic gene products causes mice to be immune tolerant to HBV Ags. Additionally, transgenic mice are not suitable for monitoring viral clearance as the integrated HBV genome persists in each mouse cell ([@bib5]; [@bib41]). Also, although successful vaccines have been developed for preventing the infection, the treatment or immunotherapy after HBV infection has not been developed. Furthermore, the experimental approaches to HBV pathogenesis have been hampered because the host range of HBV infection is limited to human beings and chimpanzees, and *in vitro* culture system for the propagation of HBV is not sufficient. CD8^+^ T cells are promising effector cells against various types of viral infection; however, T cell response against HBV is not abundant. Specificity, functioning, and lack of sufficient amount to mount an immune response may be the cause. Here, we used the method of hydrodynamic injection that capably induces HBV replication in mice. The method allows delivery of a large amount of HBV plasmid directly into the liver. The model exhibits continuous viremia for more than 8 weeks with detection of HBV mRNA, protein, and DNA at different days after injection. This method for HBV replication in mice may be a useful model for HBV immunotherapy. Of note, this method brought out a large number of infiltrating immune cells in the liver tissues ([Figures 3](#fig3){ref-type="fig"}E and [5](#fig5){ref-type="fig"}C), and we identified that the majority of these inflammatory immune cells were CD11b^+^Ly6G^+^ neutrophils ([Figure S3](#mmc1){ref-type="supplementary-material"}).

Taken together, the current study provides new insights into the mechanism and therapeutic intervention using viral Ag-specific iPSC-CTLs as immunotherapy for HBV infections. However, in the current study, the HBV hydrodynamic scheme is not a real model of chronic HBV infection, but it is a method to express HBV Ags in mouse hepatocytes. The robust mouse models for studying HBV persistence and therapeutic intervention may be the adenovirus and adeno-associated virus (AAV)-based systems ([@bib7]; [@bib35]), which mimic chronic HBV infection. However, there are still disadvantages in the mouse models in which HBV viruses are transient replication in the liver, and no real HBV viral infection as well as cccDNA formation. Nevertheless, a combination approach using α-HBV drugs with adoptive cell transfer of viral Ag-specific iPSC-CTLs is likely to reduce HBV reservoirs, thereby resulting in a remedy of HBV infections.

Limitations of the Study {#sec3.1}
------------------------

The *in vitro* generation of viral Ag-specific T lymphocytes from stem cells has not been optimized, and the iPSC-derived CD8^+^ T cells did not differentiate at the same time. We sorted dsRed^+^CD8^+^ cells for adoptive cell transfer, and the dsRed^+^CD8^+^ cells might include CD4^+^CD8^+^ (DP) cells and other CD8^+^ premature lymphocytes. After the adoptive cell transfer, the premature lymphocytes might change CD8 expression.

The robust mouse models for studying HBV persistence and therapeutic intervention may be the adenovirus and adeno-associated virus (AAV)-based systems, which mimic chronic HBV infection. However, there are still disadvantages in the mouse models in which HBV viruses are transient replication in the liver, and no real HBV viral infection as well as cccDNA formation.

Resource Availability {#sec3.2}
---------------------

### Lead Contact {#sec3.2.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jianxun Song (<jus35@tamu.edu>).

### Materials Availability {#sec3.2.2}

This study did not generate new unique reagents.

### Data and Code Availability {#sec3.2.3}

The authors confirm that the data supporting the findings of this study are available within the article and its [Supplemental Information](#appsec1){ref-type="fn"}.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Supplemental Information {#appsec2}
========================

Document S1. Transparent Methods and Figures S1--S3
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